Poster 35

Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II

Authors: Ingram J.R., Porter M., Chovatiya R., Giamarellos-Bourboulis E.J., Bechara F.G., Fujita H., Gulliver W., Muller E., Bari M., Rolleri R., Byerly R., Kirby J.S.

<PREVIOUS POSTER | NEXT POSTER>

Poster 35